# Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

> **NCT03079687** · — · APPROVED_FOR_MARKETING · sponsor: **AstraZeneca**

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib tablets

## Key facts

- **NCT ID:** NCT03079687
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03079687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03079687, "Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03079687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*